Abstract
AbstractPurpose To develop preclinical orthotopic models of primary human retinoblastomaMethods Orthotopic models of human retinoblastoma have been developed from three subcutaneous xenografted models that have previously been established and characterized in our laboratory, i.e. RB102‐FER, RB111‐MIL, and RB200‐GS that have been maintained in nude mice. Mice bearing xenografts were sacrificed and tumors were dissected to obtain a suspension of fresh tumor cells at a concentration of 8000 cells/l in DMEM serum‐free medium. Under intraperitoneal anesthesia, 2l of cell suspension was injected into the subretinal space of the right eye for 3 groups of mice using a 32G needle via a Hamilton syringe. Each group was constituted by 2 female SQUID mice and 3 male nude mice. After subretinal injection, ophthalmic examination of the mice was done every 15 days with binocular microscope. When tumor cells invaded vitreal cavity and anterior chamber, the mice were sacrificed for ophthalomological pathological analyses.Results Tumor cells developed in all injected eyes, whatever the mouse categories used, 4 weeks after orthotopic transplantation for RB102‐FER and 6 weeks after for RB200‐GS. In contrast, no tumor growth was observed in injected eyes of the RB111‐MIL model. In the 2 first xenografts, the proliferation started with a white hemorrhagic retinal mass; three weeks later, the vitreous was invaded by tumor cells that extended to the anterior chamber. Pathological examination of the injected eyes confirmed the presence of a massive infiltration of the retina, vitreous and anterior chamber by retinoblastoma cells.Conclusion We have then developed two new models of orthotopic primary human retinoblastoma that well reproduce the patient’s tumors.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.